Kate Bingham was Chair of the Vaccine Taskforce in 2020, leading the UK's efforts to find and manufacture a COVID-19 vaccine. On 8 December 2020 the UK started COVID-19 vaccinations - the first Western country to do so.
Kate has been building and investing in early stage biotech companies in the UK, EU and US at SV Health Investors since 1991. In her 30 years at SV, Kate's biotech investments have resulted in the launch of numerous first-in-class drugs for the treatment of patients with inflammatory and autoimmune disease and cancer. In 2018, Kate spearheaded the launch of the Dementia Discovery Fund - the first venture capital fund dedicated to the discovery of disease-modifying dementia drugs targeting new biological mechanisms that drive neurodegeneration.
Kate serves on the Board of the Francis Crick Institute and ARIA. She read Biochemistry at Oxford University (First Class) and has an MBA from Harvard Business School (Baker Scholar).
Professional position
- Managing Partner, SV Health Investors
Subject groups
-
Other
Other interests
